If your email does not support graphics, access the web version of this newsletter.

Fluorous Technologies, Inc. (FTI)

Fluorous Technologies, Inc. (FTI) is a chemical technology company dedicated to the development and commercialization of fluorous products focused at the life science market. The company uses patented technology to solve synthesis and separation problems spanning the entire drug discovery and development process. FTI further leverages its enabling technology through service contracts, licenses, and collaborations.

Fluorous Technologies and Biotage Sign Exclusive Manufacturing and Distribution Agreement

Now you can take your fluorous chemistry to a new scale by simply using Biotage FLASH+™ chromatography cartridges and Samplet™ sample-loading cartridges. In an exclusive agreement, Biotage will manufacture, market, and sell several sizes of its standard cartridges packed with FTI's FluoroFlash™ silica gel. When used with Biotage's Horizon™ automated High-Performance FLASH Chromatography (HPFC) system, every bench chemist can take their separations to a new level. Please call Biotage at 1-800-446-4752 or see your FTI sales representative for more information. Click here for a more detailed press release.

Fluorous Reactions Enter Prime Time

Two recent authoritative reviews emphasize that fluorous chemistry can be routinely used to solve real world problems in process and discovery chemistry. In a review entitled "Tag strategy for separation and recovery" (Chem. Rev. 2002, 102, 3693), Yoshida and Itami from Kyoto highlight the advantages of fluorous reagents, tags, and catalysts in comparison with solid phase and other options. The fluorous approach compares very favorably! And Dobbs from Exeter writes in "Fluorous Phase Chemistry: a new industrial technology" (J. Fluorine Chem., 2003, 118, 3) that fluorous chemistry "is ripe for adoption by the chemical community as a whole". Do you still think that fluorous chemistry is an interesting academic curiosity? Think again. In addition to these reviews, FTI provides lots of practical information on what is available and how to use it on our web site at www.fluorous.com

Fluorous Technologies for Library Synthesis

Come see us at CHI's Advancing Library Design & Organic Assisted Synthesis Conference February 24-27, 2003 in La Jolla, California. There you can learn how Fluorous Technologies can generate solution phase targeted libraries for your hit-to-lead needs. As a guest of Fluorous Technologies, you are entitled to a discount! Mention the code LDSFT to receive $100 off the commercial rate or $50 off the academic rate. To register call Kris at 617-630-1313 or email kwaterman@healthtech.com www.healthtech.com.

Fluorous Chemistry Continues to Grow by Leaps and Bounds in 2002

An analysis of publications for the year 2002 shows that interest in fluorous chemistry continues on a steep upward slope. CAPlus lists 122 citations of "fluorous" in 2002. That's an increase of over 50% from 2001 and accounts for about 25% of all citations since 1994. The diversity of these papers and patents-from catalysis to drug discovery to separation science to biology to material and polymer chemistry and beyond-shows the breadth of the field. There's something fluorous for everyone.

Cutting Edge Fluorous Chemistry

Fluorous Biphasic Esterification Directed towards High Atom Efficiency: The application of fluorous biphasic catalysis (FBC) to eesterifications was recently described by Junzo Otera and coworkers (Angew. Chem. Int. Ed. 2002, 41, 21) from Okayama University of Science, Japan. By taking advantage of the unique properties of a fluorous stannoxane catalyst, Otera and co-workers obtained exceptionally high yields with ester and alcohol reactants in 1:1 ratio. The general scheme is outlined in Fig 1. Equimolar amounts of acid and alcohol are mixed with a catalytic amount of fluorous stannoxane dissolved in a fluorous solvent. Upon heating the mixture becomes homogenous. Once complete, the reaction is cooled. Extraction with toluene provides an organic phase containing the desired product and a fluorous phase containing the fluorous catalyst. Primary alcohols and sterically undemanding acids typically provided yields from 90% to 100%. Yields were seen to drop when more sterically demanding substrates were employed.

Fig. 1:Fluorous Biphasic Catalysis Esterification Scheme

a) 1:1 mixture of RCOOH and ROH together with catalyst (C₆F₁₃C₂H₄)₂SnOSn(C₂H₄C₆F₁₃)₂Cl}₂ in FC-72 (perfluorohexanes) was heated at 150 degrees C.

b) Extraction with toluene and separation of phases.

The reaction is highlighted by its high atom efficiency. Equimolar quantities of both reactants are used and the reaction solvent and catalyst are recyclable. The catalyst was recovered from the FC-72 layer with excellent mass recovery, but not in pure form. Nonetheless, the recovered catalyst exhibited similar activity to that of the original. Otera and coworkers recycled the catalytic solution up to 10 times while retaining high yields and comparable activity. The high atom efficiency, in combination with a facile recovery and reuse of the catalyst, demonstrates the potential of FBC in developing green processes.

FTI can provide a full range of services to meet your chemistry needs, including custom synthesis, process development, and contract research.

For further information please contact FTI at 412-826-3050. We value your privacy. To learn more about how FTI uses personal information, consult our privacy policy. To unsubscribe from this newsletter, please reply to this email with "unsubscribe" in the subject line.

Biotage, Inc., a wholly-owned subsidiary of Dyax Corp. (Nasdaq: DYAX) of Cambridge, MA, is a global industry leader in small-molecule drug discovery purification systems and consumables for the pharmaceutical industry. Its worldwide headquarters are located in Charlottesville, Virginia, USA with offices in Hertford, England; Duesseldorf, Germany; Milan, Italy and Tokyo, Japan. For additional information, visit www.biotage.com.

Biotage Disclaimer: This newsletter contains forward-looking statements, including statements regarding the prospects for the combination of Biotage's HPFC platform products with FluoroFlash™ fluorinated silica. Statements that are not historical facts are based on Biotage's current expectations, beliefs, assumptions, estimates, forecasts and projections about the industry and markets in which Biotage competes. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors which may affect the prospects for the combination of Biotage's HPFC platform products with FluoroFlash™ fluorinated silica include the risks that: the product combination may not gain market acceptance or may be made less effective or obsolete by competing technologies or products; Biotage may not be able to obtain and maintain intellectual property protection for its products; others may develop technologies or products superior to Biotage's products; and other risk factors described or referred to in Dyax's most recent Annual Report on Form 10-K and other periodic reports filed with the Securities and Exchange Commission. Biotage and Dyax caution investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Biotage and Dyax undertake no obligations to update or revise these statements, except as may be required by law.

Dyax and the Dyax logo are registered trademarks of Dyax Corp. Biotage, Samplet, and Flash+ are trademarks of Biotage, Inc., a Dyax subsidiary. FluoroFlash™ is a trademark of Fluorous Technologies, Inc.